Novo Nordisk EVP: Semaglutide can double obesity business in few years

Now that the FDA has approved Novo Nordisk's semaglutide as an injection treatment for obesity, the pharmaceutical company expects to double its sales of obesity drugs.

Novo Nordisk EVP, Head of Development, Martin Holst Lange | Photo: Novo Nordisk / PR

Now that Danish pharmaceutical company Novo Nordisk has an approval from the US Food and Drug Administration (FDA) in place, Novo Nordisk is ready to launch the obesity drug Wegovy on the US market in late June.

The company is already present on the obesity market with the drug Saxenda. It expects that the new product, which uses semaglutide as an injection-based treatment, will increase sales and give Novo Nordisk access to this unexploited market.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs